Ovarian Cancer Plasma
Ovarian Cancer Plasma is collected from IRB-consented donors with clinically confirmed ovarian cancer. Ideal for circulating tumour DNA and liquid biopsy work, CA-125 and HE4 marker research, plasma proteomics, and early-detection biomarker discovery. Available stratified by stage, histology, treatment timepoint and platinum sensitivity, with age-matched healthy controls.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 76645 | Ovarian Cancer | 2.0 ML | 53 | Female | Ukraine |
No medications
|
1 | $667.00 | ||
| 76749 | Ovarian Cancer | 1.0 ML | 47 | Female | Ukraine |
No medications
|
1 | $667.00 | ||
| 76748 | Ovarian Cancer | 1.0 ML | 47 | Female | Ukraine |
No medications
|
1 | $667.00 | ||
| 76640 | Ovarian Cancer | 1.0 ML | 57 | Female | Ukraine |
No medications
|
1 | $667.00 | ||
| 76642 | Ovarian Cancer | 1.0 ML | 69 | Female | Ukraine |
No medications
|
1 | $667.00 | ||
| 76638 | Ovarian Cancer | 5.0 ML | 70 | Female | Ukraine |
No medications
|
1 | $667.00 | ||
| 76646 | Ovarian Cancer | 2.0 ML | 73 | Female | Ukraine |
Cardiomagnyl
|
1 | $667.00 |
Ovarian Cancer Plasma for Tumour Biomarker and Liquid Biopsy Research
Ovarian Cancer Plasma is collected from IRB-consented donors clinically diagnosed with ovarian cancer and processed within one day of collection to preserve proteins, nucleic acids and metabolites. Plasma is acellular, so this product is intended for soluble-analyte and cell-free nucleic acid work rather than cell-based assays.
Ovarian Cancer Biology and Why Plasma
Ovarian cancer is a neoplastic disease. The relevant biology is tumour biology and tumour immunology, not autoimmunity.
- High-grade serous carcinoma is the most common and most lethal histological subtype, and is characterised by near-universal TP53 mutation and widespread copy number instability
- Defects in homologous recombination repair, notably germline or somatic BRCA1 and BRCA2 alterations, define the subgroup that responds to PARP inhibition
- CA-125 is the long-established circulating protein marker used to monitor disease, with HE4 studied as a complementary analyte; neither is adequate as a standalone screening test in the general population
- Late-stage presentation with peritoneal dissemination is typical, which is why early-detection biomarker research remains a major focus for this indication
- Circulating tumour DNA is shed into plasma and enables mutation detection, copy number analysis and treatment-response monitoring without repeat tissue sampling
- Plasma is the required matrix for cell-free DNA work and supports proteomic, extracellular vesicle and metabolomic discovery from the same collection
Donor Stratification Available
- Histological subtype, including high-grade serous where documented
- FIGO stage at diagnosis
- Treatment timepoint: treatment-naive, on platinum-based chemotherapy, or post-treatment surveillance
- Platinum-sensitive versus platinum-resistant disease
- BRCA1/BRCA2 or homologous recombination deficiency status where tested
- CA-125 level at collection where available
- Matched healthy controls available, age-matched on request
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed ovarian cancer donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
- Anticoagulant and cell-free DNA tube options available on request
De-identified Donor Data
- Verified ovarian cancer diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Stage, histology and treatment history where available
- Additional ovarian cancer-specific metadata available
Applications
- Circulating tumour DNA detection and liquid biopsy assay development
- CA-125, HE4 and multi-analyte tumour marker panel research
- Early-detection biomarker discovery and validation
- Plasma proteomics and untargeted metabolomics
- Extracellular vesicle and circulating miRNA profiling
- Treatment-response and platinum-resistance monitoring research
- Soluble immune checkpoint and cytokine measurement in tumour immunology
- Case-control comparisons against age-matched healthy donors
Other Ovarian Cancer Specimen Types
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Ovarian Cancer plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse plasma from other disease states and check live stock status, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.